Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. [electronic resource]
Producer: 20190809Description: 969-980 p. digitalISSN:- 1476-5551
- Adenine -- analogs & derivatives
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bendamustine Hydrochloride -- administration & dosage
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Male
- Middle Aged
- Piperidines
- Prognosis
- Pyrazoles -- administration & dosage
- Pyrimidines -- administration & dosage
- Rituximab -- administration & dosage
- Survival Rate
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.